logo-loader
viewAllergy Therapeutics PLC

Allergy Therapeutics shares tipped to rise to 32p

Allergy Therapeutics plc (LON:AGY) has a chance of rising to around 32p per share, so says technical analyst Zak Mir.

In a Tip TV segment for Proactive Investors, Mir highlights the big turnaround in the chart for Allergy Therapeutics and notes that it is now in a rising trend.

Quick facts: Allergy Therapeutics PLC

Price: 10.85 GBX

AIM:AGY
Market: AIM
Market Cap: £69.02 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Allergy Therapeutics on track for phase III grass pollen trial in 2019

Manuel Llobet, chief executive of Allergy Therapeutics plc (LON:AGY), spoke to Proactive Investors after reporting  “extremely positive results” from the phase II trial of their grass pollen-induced hay fever immunotherapy. Llobet says PQ Grass met its primary endpoint, with those...

on 21/5/18

2 min read